These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24696429)

  • 1. Paying for formerly free medicines in Spain after 1 year of co-payment: changes in the number of dispensed prescriptions.
    Puig-Junoy J; Rodríguez-Feijoó S; Lopez-Valcarcel BG
    Appl Health Econ Health Policy; 2014 Jun; 12(3):279-87. PubMed ID: 24696429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does €1 Per Prescription Make a Difference? Impact of a Capped Low-Intensity Pharmaceutical Co-Payment.
    García-Gómez P; Mora T; Puig-Junoy J
    Appl Health Econ Health Policy; 2018 Jun; 16(3):407-414. PubMed ID: 29549661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Changes in Cost Sharing on the Consumption of Prescription and Over-the-Counter Medicines in Catalonia.
    Martínez-Jiménez M; García-Gómez P; Puig-Junoy J
    Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33806543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.
    Chen LC; Schafheutle EI; Noyce PR
    Res Social Adm Pharm; 2009 Sep; 5(3):211-24. PubMed ID: 19733822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Social inequalities and pharmaceutical cost sharing in Italian regions.
    Terraneo M; Sarti S; Tognetti Bordogna M
    Int J Health Serv; 2014; 44(4):761-85. PubMed ID: 25626227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Aust N Z J Public Health; 2009 Jun; 33(3):246-52. PubMed ID: 19630844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Sharing Rates Increase During Deep Recession: Preliminary Data From Greece.
    Gouvalas A; Igoumenidis M; Theodorou M; Athanasakis K
    Int J Health Policy Manag; 2016 May; 5(12):687-692. PubMed ID: 28005548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a change in co-payment on prescription drug demand in a National Health System: The case of 15 drug families by price elasticity of demand.
    Hernández-Izquierdo C; González López-Valcárcel B; Morris S; Melnychuk M; Abásolo Alessón I
    PLoS One; 2019; 14(3):e0213403. PubMed ID: 30917142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions.
    Anis AH; Guh DP; Lacaille D; Marra CA; Rashidi AA; Li X; Esdaile JM
    CMAJ; 2005 Nov; 173(11):1335-40. PubMed ID: 16301701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost of prescription medicines to patients.
    Noyce PR; Huttin C; Atella V; Brenner G; Haaijer-Ruskamp FM; Hedvall M; Mechtler R
    Health Policy; 2000 Jun; 52(2):129-45. PubMed ID: 10794841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free prescriptions for low-income pensioners? The cost of returning to free-of-charge drugs in the Spanish National Health Service.
    Puig-Junoy J; Pinilla J
    Health Econ; 2020 Dec; 29(12):1804-1812. PubMed ID: 32931075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of prescription practices and of the rational use of medicines in Niger].
    Mallet HP; Njikam A; Scouflaire SM
    Sante; 2001; 11(3):185-93. PubMed ID: 11641083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explaining primary healthcare pharmacy expenditure using classification of medications for chronic conditions.
    Vivas D; Guadalajara N; Barrachina I; Trillo JL; Usó R; de-la-Poza E
    Health Policy; 2011 Nov; 103(1):9-15. PubMed ID: 21956046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.